真实世界环境中接受放疗的浸润性膀胱癌患者新辅助顺铂化疗的获益:一项逆概率治疗加权分析
本研究在加拿大各学术中心纳入785例接受根治性放疗的肌层浸润性膀胱癌(MIBC)患者,最终分析586例,其中102例(17%)在放疗前接受新辅助化疗(NAC)。经逆概率治疗加权后,NAC与癌症特异性生存改善(HR 0.28;95%CI 0.14-0.56;p<0.001)和总生存改善(HR 0.56;95%CI 0.38-0.84;p=0.005)显著相关。作者认为若可耐受,NAC或与生存改善相关,应考虑用于计划接受放疗保留膀胱的合格MIBC患者,并需前瞻性试验验证。
要点
- 在真实世界接受根治性放疗的MIBC患者中,放疗前NAC与癌症特异性生存改善相关(HR 0.28;95%CI 0.14-0.56;p<0.001)。
- 放疗前NAC与总生存改善相关(HR 0.56;95%CI 0.38-0.84;p=0.005)。
- 作者认为若可耐受,NAC应考虑用于计划接受放疗保留膀胱的合格MIBC患者。
核心结论
- 若可耐受,NAC或与接受根治性放疗的MIBC患者生存改善相关,作者认为应考虑用于计划接受放疗保留膀胱的合格患者。
- 作者指出需开展前瞻性试验。
研究设计与样本
- 研究为真实世界队列,纳入加拿大各学术中心785例接受根治性放疗的MIBC患者(cT2-4aN0-2M0)。
- 按放疗前是否接受NAC分为NAC组与无NAC组,采用逆概率治疗加权(IPTW)以绝对标准化差异(ASD)平衡协变量。
- 应用排除标准后共586例纳入分析,其中102例(17%)接受放疗前NAC。
主要发现
- NAC组患者更年轻(平均年龄65岁 vs 77岁;ASD 1.20)。
- NAC组更常见ECOG体能状态0-1(87% vs 78%;ASD 0.28)、淋巴血管侵犯(32% vs 20%;ASD 0.27)、较高cT分期(cT3-4占29% vs 20%;ASD 0.21)和较高cN分期(cN1-2占32% vs 4%;ASD 0.81)。
- NAC组更常接受同步化疗(79% vs 67%;ASD 0.28)。
- IPTW后,NAC组与无NAC组所有纳入协变量均平衡良好(ASD<0.20)。
- NAC与癌症特异性生存改善显著相关(HR 0.28;95%CI 0.14-0.56;p<0.001),与总生存改善显著相关(HR 0.56;95%CI 0.38-0.84;p=0.005)。
关键数值与推荐
- NAC组102例(17%)接受放疗前NAC。
- NAC与癌症特异性生存:HR 0.28(95%CI 0.14-0.56;p<0.001)。
- NAC与总生存:HR 0.56(95%CI 0.38-0.84;p=0.005)。
临床怎么用
- 作者认为若可耐受,NAC应考虑用于计划接受放疗保留膀胱的合格MIBC患者。
- 作者指出需开展前瞻性试验。
局限性
- 本研究受限于治疗组间可能存在的隐匿性失衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neoadjuvant chemotherapy (NAC) improves survival for patients with muscle-invasive bladder cancer (MIBC) treated with radical cystectomy. Studies on the potential benefit of NAC before radiation-based therapy (RT) are conflicting. OBJECTIVE: To evaluate the effect of NAC on patients with MIBC treated with curative-intent RT in a real-world setting. DESIGN, SETTING, AND PARTICIPANTS: The study cohort consisted of 785 patients with MIBC (cT2-4aN0-2M0) who underwent RT at academic centers across Canada. Patients were classified into two treatment groups based on the administration of NAC before RT (NAC vs no NAC). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The inverse probability of treatment weighting (IPTW) with absolute standardized differences (ASDs) was used to balance covariates across treatment groups. The impact of NAC on complete response, overall, and cancer-specific survival (CSS) after RT in the weighted cohort was analyzed. RESULTS AND LIMITATIONS: After applying the exclusion criteria, 586 patients were included; 102 (17%) received NAC before RT. Patients in the NAC subgroup were younger (mean age 65 vs 77 yr; ASD 1.20); more likely to have Eastern Cooperative Oncology Group performance status 0-1 (87% vs 78%; ASD 0.28), lymphovascular invasion (32% vs 20%; ASD 0.27), higher cT stage (cT3-4 in 29% vs 20%; ASD 0.21), and higher cN stage (cN1-2 in 32% vs 4%; ASD 0.81); and more commonly treated with concurrent chemotherapy (79% vs 67%; ASD 0.28). After IPTW, NAC versus no NAC cohorts were well balanced (ASD <0.20) for all included covariates. NAC was significantly associated with improved CSS (hazard ratio [HR] 0.28; 95% confidence interval [CI] 0.14-0.56; p < 0.001) and overall survival (HR 0.56; 95% CI 0.38-0.84; p = 0.005). This study was limited by potential occult imbalances across treatment groups. CONCLUSIONS: If tolerated, NAC might be associated with improved survival and should be considered for eligible patients with MIBC planning to undergo bladder preservation with RT. Prospective trials are warranted. PATIENT SUMMARY: In this study, we showed that neoadjuvant chemotherapy might be associated with improved survival in patients with muscle-invasive bladder cancer who elect for curative-intent radiation-based therapy.
引用
- Kool R, Dragomir A, Kulkarni GS, et al. Benefit of Neoadjuvant Cisplatin-based Chemotherapy for Invasive Bladder Cancer Patients Treated with Radiation-based Therapy in a Real-world Setting: An Inverse Probability Treatment Weighted Analysis. Eur Urol Oncol. 2024. PMID: 38326142. doi:10.1016/j.euo.2024.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。